{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:40:56Z","timestamp":1784259656898,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12185-018-2553-9","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T04:24:45Z","timestamp":1540441485000},"page":"228-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-5950","authenticated-orcid":false,"given":"Tadashi","family":"Kumamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Yamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanaka","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitose","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"2553_CR1","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/1097-0142(19841101)54:9<1834::AID-CNCR2820540911>3.0.CO;2-F","volume":"54","author":"E Foucar","year":"1984","unstructured":"Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer. 1984;54:1834\u201340.","journal-title":"Cancer"},{"key":"2553_CR2","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","volume":"131","author":"O Abla","year":"2018","unstructured":"Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131:2877\u201390.","journal-title":"Blood"},{"key":"2553_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00428-017-2176-1","volume":"471","author":"F Facchetti","year":"2017","unstructured":"Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, et al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Arch. 2017;471:467\u201389.","journal-title":"Virchows Arch"},{"key":"2553_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/his.12416","volume":"65","author":"H Go","year":"2014","unstructured":"Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65:261\u201372.","journal-title":"Histopathology"},{"key":"2553_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00428-016-1965-2","volume":"469","author":"Q Liu","year":"2016","unstructured":"Liu Q, Tomaszewicz K, Hutchinson L, Hornick JL, Woda B, Yu H. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. Virchows Arch. 2016;469:233\u201341.","journal-title":"Virchows Arch"},{"key":"2553_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/modpathol.2017.174","volume":"31","author":"X Tian","year":"2018","unstructured":"Tian X, Xu J, Fletcher C, Hornick JL, Dorfman DM. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1\/2-related, but not MYC- or p-STAT3-related cell signaling. Mod Pathol. 2018;31:553\u201361.","journal-title":"Mod Pathol"},{"key":"2553_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamaoncol.2015.5689","volume":"2","author":"MH Harris","year":"2016","unstructured":"Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. JAMA Oncol. 2016;2:608\u201315.","journal-title":"JAMA Oncol"},{"key":"2553_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.009","volume":"65","author":"BC Worst","year":"2016","unstructured":"Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generation personalised medicine for high-risk paediatric cancer patients\u2014the INFORM pilot study. Eur J Cancer. 2016;65:91\u2013101.","journal-title":"Eur J Cancer"},{"key":"2553_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jama.2015.10080","volume":"314","author":"RJ Mody","year":"2015","unstructured":"Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314:913\u201325.","journal-title":"JAMA"},{"key":"2553_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","volume":"30","author":"S Garces","year":"2017","unstructured":"Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30:1367\u201377.","journal-title":"Mod Pathol"},{"key":"2553_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMc1511490","volume":"378","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Solit DB, Tap WD. Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation. N Engl J Med. 2018;378:1945\u20137.","journal-title":"N Engl J Med"},{"key":"2553_CR12","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-14-2124","volume":"21","author":"ME Arcila","year":"2015","unstructured":"Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res. 2015;21:1935\u201343.","journal-title":"Clin Cancer Res"},{"key":"2553_CR13","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.3324\/haematol.2017.179150","volume":"103","author":"S Voruz","year":"2018","unstructured":"Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica. 2018;103:e39\u201341.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2553-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T16:33:57Z","timestamp":1572021237000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2553-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2553-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"30 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}